

#### **About Spherix Global Insights**

Spherix is the world's leading Life Sciences market intelligence and advisory services firm, providing unrivaled knowledge and the most informed, actionable insights.

We bring human intelligence to market intelligence. Spherix empowers customers to access critical insights that drive successful decision-making through deep, expert knowledge.

#### **Spherix Provides Independent Expertise in Seven Areas**



**Dermatology** 



**Nephrology** 



Gastroenterology



Neurology



Rheumatology



**Ophthalmology** 



This is a guide to the publications Spherix will produce in 2024. It is organized by therapeutic area, indication, and deliverable.

#### **Going Beyond the Data**

The report is only the beginning. Spherix brings curation and interpretation to market intelligence, working closely with customers to reveal actionable insights that transform markets.

Type of Publications		
MARKET DYNAMI/	A yearly market overview of an indication, Market Dynamix provides insights into current treatment paradigms and unmet patient needs as well as physician opinions on how they will likely prescribe new products upon approval.	
REALTIME DYNAMIX	A US quarterly or EU5 semi-annual update on an indication, RealTime Dynamix provides trending content on brand use, future intentions, promotional activity, disease awareness and controversy, and pipeline product perceptions.	
LAUNCH DYNAMI/	Published monthly, Launch Dynamix tracks a new brand's first eighteen months of commercial availability. Each quarter includes a deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.	
PATIENT CHART DYNAMIX	A yearly large-scale patient chart audit on an indication, Patient Chart Dynamix unmasks real patient management patterns an uncovers the "why" behind treatment decisions.	
SPECIAL TOPIX	Whether the focus is breaking industry news, ongoing trends, conference coverage, or quick-pulse reactions, Special Topix assesses the impact of events in our specialty markets.	

For a complete index of available reports, visit www.clientportal.spherixglobalinsights.com



### 2025 Dermatology Publications



Atopic Dermatitis	
MARKET DYNAMI/	Atopic Dermatitis, US
REALTIME DYNAMI/	<ul><li>Atopic Dermatitis, EU5</li><li>Atopic Dermatitis, JP/ CH</li></ul>
LAUNCH DYNAMI/	<ul> <li>Ebglyss (Eli Lilly) in Atopic Dermatitis, US</li> <li>Nemluvio (Galderma) in Atopic Dermatitis, US</li> <li>Vtama and Zoryve (Arcutis/ Dermavant) in Atopic Dermatitis, US</li> </ul>
PATIENT CHART DYNAMIX	Atopic Dermatitis, US

Alopecia Areata	
MARKET DYNAMI/	Alopecia Areata, US
LAUNCH DYNAMIX	<ul> <li>Leqselvi (SUN Pharma) in Alopecia Areata, US</li> <li>Litfulo (Pfizer) in Alopecia Areata, US</li> </ul>

	Hidradenitis Suppurativa
MARKET DYNAMI/	Hidradenitis Suppurativa, US
REALTIME DYNAMIX	Hidradenitis Suppurativa, EU5
LAUNCH DYNAMI/	<ul> <li>Bimzelx (UCB) in Hidradenitis Suppurativa, US*</li> <li>Cosentyx (Novartis) in Hidradenitis Suppurativa, US</li> </ul>
PATIENT CHART DYNAMIX	Hidradenitis Suppurativa, US

• Chronic Spontaneous Urticaria, US

MARKET • Asthma. US	Dermatology Related Respiratory	
DYNAMI/ • Chronic Spontaneous Urticaria US	MARKET	Asthma, US

	Plaque Psoriasis
REALTIME DYNAMI/	<ul><li>Plaque Psoriasis, US</li><li>Plaque Psoriasis, EU5</li></ul>
LAUNCH DYNAMIX	Bimzelx (UCB) in Plaque Psoriasis, US
PATIENT CHART DYNAMI/	Plaque Psoriasis, US
SPECIAL TOPIX	The Oral Opportunity in Plaque Psoriasis, US

Other Dermatology Indications	
MARKET DYNAMI/	<ul><li> Prurigo Nodularis, US</li><li> Vitiligo, US</li></ul>
LAUNCH DYNAMIX	<ul> <li>Dupixent (Sanofi/Regeneron) in Chronic Spontaneous Urticaria, US</li> <li>Dupixent (Sanofi/Regeneron) in Chronic Obstructive Pulmonary Disease, US</li> <li>Remibrutinib (Novartis) in Chronic Spontaneous Urticaria, US</li> <li>Nemluvio (Galderma) in Prurigo Nodularis, US</li> </ul>
SPECIAL TOPI/	<ul> <li>Biologic Coordinators Across Dermatology, US</li> <li>Awareness and Expected Impact of IRA Changes in 2025</li> </ul>

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
SPECIAL TOPIX	Current events on specific interest areas



### 2025 Gastroenterology Publications



	Eosinophilic Esophagitis
MARKET DYNAMI/	<ul><li>Eosinophilic Esophagitis, US</li><li>Eosinophilic Esophagitis, EU5</li></ul>
LAUNCH DYNAMIX	Eohilia (Takeda) in Eosinophilic Esophagitis, US

In	flammatory Bowel Disease
REALTIME DYNAMI/	<ul> <li>Crohn's Disease, US</li> <li>Crohn's Disease, EU5</li> <li>Ulcerative Colitis, US</li> <li>Ulcerative Colitis, EU5</li> </ul>
LAUNCH DYNAMIX	<ul> <li>Entyvio SC (Takeda) in Crohn's Disease, US</li> <li>Tremfya (Janssen) in Crohn's Disease, US*</li> <li>Omvoh (Eli Lilly) in Crohn's Disease, US*</li> <li>Entyvio SC (Takeda) in Ulcerative Colitis, US</li> <li>Omvoh (Eli Lilly) in Ulcerative Colitis, US</li> <li>Skyrizi (AbbVie) in Ulcerative Colitis, US</li> <li>Tremfya (Janssen) in Ulcerative Colitis, US</li> <li>Velsipity (Pfizer) in Ulcerative Colitis, US</li> </ul>

• Inflammatory Bowel Disease New Starts, US

Inflammatory Bowel Disease Switching, USInflammatory Bowel Disease Switching, EU5

Metabolic Dysfunction-associated Steatotic Liver Disease / Metabolic Dysfunction-associated Steatohepatitis	
MARKET DYNAMI/	• MASLD/MASH, US
LAUNCH DYNAMIX	Rezdiffra (Madrigal) in MASLD/MASH, US
PATIENT CHART DYNAMI/	• MASLD/MASH, US

Other Gastroenterology Indications	
MARKET DYNAMI/	<ul> <li>Celiac Disease, US</li> <li>Primary Biliary Cholangitis/ Primary Sclerosing Cholangitis, US</li> </ul>
REALTIME DYNAMIX	Irritable Bowel Syndrome, US
LAUNCH DYNAMI/	<ul> <li>Iqirvo (Ipsen) in Primary Biliary Cholangitis, US</li> <li>Livdelzi (Gilead/ Cymabay) in Primary Biliary Cholangitis, US</li> </ul>
SPECIAL TOPIX	<ul> <li>The Role of Primary Care in Gastroenterology, US</li> <li>Awareness and Expected Impact of IRA Changes in 2025</li> </ul>

	MARKET DYNAMIX	Yearly market overview of key indication
ا ج	REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
e e	LAUNCH DYNAMIX	Monthly benchmark of newly launched products
<b>~</b>	PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
	SPECIAL TOPIX	Current events on specific interest areas

PATIENT CHART DYNAMI/



## 2025 Rheumatology Publications



# Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis

MARKET DYNAMI/	<ul> <li>Ankylosing Spondylitis &amp; nr-AxSpA, US</li> <li>Ankylosing Spondylitis &amp; nr-AxSpA, EU5</li> </ul>
LAUNCH	<ul> <li>Bimzelx (UCB) in Ankylosing Spondylitis &amp; nr-</li></ul>
DYNAMIX	AxSpA, US

Lupus		
MARKET DYNAMI/	<ul> <li>Systemic Lupus Erythematosus, US</li> <li>Systemic Lupus Erythematosus, EU5</li> <li>Cutaneous Lupus Erythematosus, US</li> </ul>	
REALTIME DYNAMIX	<ul><li>Lupus Nephritis, US</li><li>Lupus Nephritis, EU5</li></ul>	
LAUNCH DYNAMI/	Gazyva (Genentech) in Lupus Nephritis, US*	
PATIENT CHART DYNAMI/	<ul> <li>Lupus Nephritis, US</li> <li>Moderate to Severe SLE, US</li> <li>Moderate to Severe SLE, EU5</li> </ul>	

Psoriatic Arthritis		
MARKET DYNAMI/	Psoriatic Arthritis, EU5	
REALTIME DYNAMIX	Psoriatic Arthritis, US	
LAUNCH DYNAMI/	<ul> <li>Bimzelx (UCB) in Psoriatic Arthritis, US</li> <li>Sotyktu (BMS) in Psoriatic Arthritis, US*</li> </ul>	
PATIENT CHART DYNAMIX	Psoriatic Arthritis, US	

Other Rheumatology Indications	
MARKET DYNAMI⁄	<ul> <li>Dermatomyositis, US (2024)</li> <li>Giant Cell Arteritis, US (2024)</li> <li>Idiopathic Inflammatory Myopathy, US</li> <li>Polymyalgia Rheumatica, US (2024)</li> <li>Rheumatoid Arthritis, US</li> <li>Rheumatoid Arthritis, EU5</li> <li>Sjogren's Syndrome, US</li> <li>Systemic Sclerosis, US</li> <li>Systemic Sclerosis, EU5 (2024)</li> </ul>
LAUNCH DYNAMIX	<ul> <li>Hizentra (CSL) in Dermatomyositis, US*</li> <li>Rinvoq (AbbVie) in Giant Cell Arteritis, US*</li> </ul>
SPECIAL TOPI/	<ul> <li>Cell Therapy in Rheumatology, US</li> <li>Feedback from ACR Convergence, US</li> <li>Interstitial Lung Disease in Rheumatology, US</li> <li>Awareness and Expected Impact of IRA Changes in 2025</li> </ul>

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
SPECIAL TOPIX	Current events on specific interest areas
	REALTIME DYNAMIX  LAUNCH DYNAMIX  PATIENT CHART DYNAMIX



Kidney Disease		
MARKET DYNAMI/	<ul> <li>Autosomal Dominant Polycystic Kidney Disease, US</li> <li>Chronic Kidney Disease &amp; Diabetic Kidney Disease, US</li> </ul>	MARKET DYNAMI/
DEALTIME	<ul><li>Hyperkalemia, US</li><li>Dialysis, US</li></ul>	REALTIME DYNAMIX
REALTIME DYNAMIX	<ul><li>Dialysis, Renal Dietitians, US</li><li>Dialysis, EU5</li></ul>	LAUNCH DYNAMI/
LAUNCH DYNAMI/	<ul> <li>Xphozah (Ardelyx) in Hyperphosphatemia, US</li> <li>Xphozah (Ardelyx) in Hyperphosphatemia, Renal Dietitians, US</li> <li>Jesduvroq (GSK) in Renal Anemia, US</li> <li>Vafseo (Akebia) in Renal Anemia, US</li> <li>OLC (Unicycive) in Hyperphosphatemia, US*</li> </ul>	PATIENT CHA
PATIENT CHART DYNAMIX	<ul><li>Chronic Kidney Disease, Non-Dialysis, Nephrology, US</li><li>Dialysis, US</li></ul>	
SPECIAL TOPI/	<ul> <li>Hypertension in CKD, US</li> <li>Implications of the Dialysis Bundle (US)</li> <li>Obesity in CKD, US</li> <li>ASN Kidney Week Conference, US</li> <li>Buy and Bill in Nephrology Practices, US</li> <li>Awareness and Expected Impact of IRA Changes in 2025</li> </ul>	REALTIME DYNAMI/ PATIENT CHA DYNAMI/

Glomerular Diseases		
MARKET DYNAMI/	<ul> <li>Complement 3 Glomerulopathy, US</li> <li>Focal Segmental Glomerulosclerosis, US</li> <li>Membranous Nephropathy, US</li> </ul>	
REALTIME DYNAMIX	<ul><li>IgA Nephropathy, US</li><li>IgA Nephropathy, EU5</li></ul>	
LAUNCH DYNAMI/	<ul> <li>Fabhalta (Novartis) in IgAN, US</li> <li>Atrasentan (Novartis) in IgAN, US*</li> <li>Fabhalta (Novartis) in C3G, US*</li> </ul>	
PATIENT CHART DYNAMIX	<ul> <li>Complement 3 Glomerulopathy, US</li> <li>Focal Segmental Glomerulosclerosis, US</li> <li>IgA Nephropathy, US</li> <li>IgA Nephropathy, EU5</li> <li>IgA Nephropathy, Japan</li> <li>IgA Nephropathy, China</li> </ul>	

Lupus Nephritis		
REALTIME DYNAMI/	Lupus Nephritis, US	
PATIENT CHART DYNAMIX	• Lupus Nephritis, US	

MARKET DYNAMIX Yearly market overview of key indication

REALTIME DYNAMIX Quarterly (US) or semi-annual (EU5) indication updates

LAUNCH DYNAMIX Monthly benchmark of newly launched products

PATIENT CHART DYNAMIX Yearly review of large-scale patient chart audits

SPECIAL TOPIX Current events on specific interest areas



### 2025 Neurology Publications



Generalized Myasthenia Gravis		
REALTIME DYNAMI/	<ul><li>Generalized Myasthenia Gravis, US</li><li>Generalized Myasthenia Gravis, EU5</li></ul>	
LAUNCH DYNAMIX	SC Biologics in Generalized Myasthenia Gravis, US	
PATIENT CHART DYNAMI/	General Myasthenia Gravis, US	

Multiple Sclerosis		
MARKET DYNAMI/	Multiple Sclerosis, US	
REALTIME DYNAMI/	<ul><li>Multiple Sclerosis, US</li><li>Multiple Sclerosis, Canada</li></ul>	
LAUNCH DYNAMI/	Ocrevus Zunovo SC (Genentech) in Multiple Sclerosis, US	

Migraine	
MARKET DYNAMI/	Migraine, US
REALTIME DYNAMIX	Migraine, US
LAUNCH DYNAMI/	Zavzpret (Pfizer) in Acute Migraine, US

	Alzheimer's Disease
REALTIME DYNAMI/	<ul><li>Alzheimer's Disease, US</li><li>Alzheimer's Disease, EU5</li></ul>
LAUNCH DYNAMIX	<ul> <li>Leqembi (Eisai/Biogen) in Alzheimer's Disease, US</li> <li>Kisunla (Eli Lilly) in Alzheimer's Disease, US</li> </ul>
PATIENT CHART DYNAMI/	Alzheimer's Disease, US
SPECIAL TOPIX	<ul> <li>Alzheimer's Disease Modifying Therapies vs. Symptomatics, US</li> </ul>

Other Neurology Indications		
MARKET DYNAMI/	<ul> <li>Amyotrophic Lateral Sclerosis, US</li> <li>Chronic Inflammatory Demyelinating, US</li> <li>Polyneuropathy, US</li> <li>Epilepsy, US</li> <li>Parkinson's Disease, US</li> <li>Huntington's Disease, US</li> </ul>	
SPECIAL TOPIX	<ul> <li>Practice Dynamix in Neurology, US</li> <li>Opportunities in the Neurology Pipeline, US</li> <li>Awareness and Expected Impact of IRA Changes in 2025</li> </ul>	

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
SPECIAL TOPIX	Current events on specific interest areas



### 2025 Ophthalmology Publications



Diabetic Macular Edema		Ot	her Ophthalmology Indications
REALTIME DYNAMI/	Diabetic Macular Edema, US	MARKET DYNAMI/	<ul><li>Chronic Dry Eye, US</li><li>Diabetic Retinopathy, US</li><li>Glaucoma, US</li></ul>
PATIENT CHART DYNAMIX	Diabetic Macular Edema, US	LAUNCH DYNAMIX	• Eylea (Regeneron/Bayer) in Retinal Disorders, US
Geographic Atrophy		SPECIAL TOPI./	<ul> <li>Business of Ophthalmology, US</li> <li>Gene Therapies in Retina, US</li> <li>Pinalina Opportunities in Ophthalmology, US</li> </ul>
LAUNCH DYNAMI/	Syfovre (Apellis) and Izervay (Iveric Bio) in Geographic Atrophy, US		<ul> <li>Pipeline Opportunities in Ophthalmology, US</li> <li>Retinal Vein Occlusion, US</li> <li>Awareness and Expected Impact of IRA Changes in 2025</li> </ul>
2110 1110	Оеодтартіс Атторту, ОЗ		

Neovascular Age-Related  Macular Degeneration		
REALTIME DYNAMI/	Neovascular Age-Related Macular Degeneration, US	
PATIENT CHART DYNAMIX	Neovascular Age-Related Macular Degeneration - Switching, US	

• Geographic Atrophy, US

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
SPECIAL TOPIX	Current events on specific interest areas
	REALTIME DYNAMIX  LAUNCH DYNAMIX  PATIENT CHART DYNAMIX

MARKET DYNAMIX



## 2025 Hematology Publications



#### **Paroxysmal Nocturnal Hemoglobinuria**

MARKET DYNAMI/	Paroxysmal Nocturnal Hemoglobinuria, EU5
REALTIME DYNAMIX	Paroxysmal Nocturnal Hemoglobinuria, US
LAUNCH DYNAMI/	• Innovations in PNH (Fabhalta (iptacopan), Voydeya (danicopan), and Piasky (crovalimab)), US
PATIENT CHART DYNAMIX	Paroxysmal Nocturnal Hemoglobinuria, US

Blood Clotting Disorders	
MARKET DYNAMI/	<ul><li>Hemophilia, US</li><li>Hemophilia, EU5</li></ul>
LAUNCH DYNAMIX	Beqvez in Hemophilia B

## Hemoglobinopathies Sickle Cell Disease and Thalassemia

MARKET DYNAMI/	<ul><li>Sickle Cell Disease, US</li><li>Thalassemia, US</li></ul>
LAUNCH DYNAMIX	<ul> <li>Casgevy and Lyfgenia in Sickle Cell Disease and Beta-Thalassemia, US</li> </ul>
PATIENT CHART DYNAMI/	<ul><li>Sickle Cell Disease, US</li><li>Thalassemia, US</li></ul>

#### **Other Benign Hematology Indications**

MARKET	<ul> <li>Cold Agglutin Disease (CAD)</li> <li>Graft vs. Host Disease (GvHD)</li> <li>Thrombocytopenia (Including ITP and TTP)</li> <li>Warm Autoimmune Hemolytic Anemia</li></ul>
DYNAMI/	(w-AIHA)
SPECIAL	<ul> <li>Adoption and Impact of Gene Therapy in</li></ul>
TOPIX	Hematology <li>Multi-Specialty Approach to aHUS</li>

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
SPECIAL TOPIX	Current events on specific interest areas

#### Visit The Spherix Portal



